IPOS
9903234-4

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :
C07D 401/14, 401/04, A61K 31/505, C07D 417/06, 403/14, 413/14, 417/14

A1

(11) International Publication Number: **WO 98/38187**

(43) International Publication Date: 3 September 1998 (03.09.98)

(21) International Application Number: PCT/IB98/00151

(22) International Filing Date: 6 February 1998 (06.02.98)

(30) Priority Data:
60/038,540 28 February 1997 (28.02.97) US

(71) Applicant *(for all designated States except US)*: PFIZER PRODUCTS INC. [US/US]; Eastern Point Road, Groton, CT 06340 (US).


(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: CHENARD, Bertrand, Leo [US/US]; 7 Whaling Drive, Waterford, CT 06385 (US). DEVRIES, Keith, Michael [US/US]; 4 Waterhouse Lane, Chester, CT 06412 (US). WELCH, Willard, McKowan, Jr. [US/US]; 116 Pequot Avenue, Mystic, CT 06355 (US).

(74) Agents: SPIEGEL, Allen, J. et al.; Pfizer Inc., Patent Dept., 235 East 42nd Street, New York, NY 10017 (US).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
With international search report.

(54) Title: ATROPISOMERS OF 3–HETEROARYL–4(3H)–QUINAZOLINONES FOR THE TREATMENT OF NEURODEGENERATIVE AND CNS–TRAUMA RELATED CONDITIONS



(1a)

(57) Abstract

The present invention relates to novel atropisomers of 3–heteroaryl–4(3H)–quinazolinones of formula (1a), and their pharmaceutically acceptable salts, and pharmaceutical compositions and methods of treating neurodegenerative and CNS–trauma related conditions.